Cormorant Asset Management, LLC Buys Acceleron Pharma Inc, Agenus Inc, Eidos Therapeutics Inc, Sells Reata Pharmaceuticals Inc, Mirati Therapeutics Inc, ChemoCentryx Inc

• New Purchases: XLRN, AGEN, CABA, FIXX, INSM, ARCT, FATE,
• Added Positions: EIDX, OMER, BBIO, ANAB, VIE, PRNB, BPMC, MYOV, YMAB, SRNE, TBPH, XFOR, ZLAB,
• Reduced Positions: RETA, MRTX, CCXI, CRSP, TPTX, ASND, NXTC, APLS, SRPT, CNST, AXNX, QURE, AXSM, ALLK, AMRN, BHVN, DCPH, RCKT, MRUS, ARGX, QTNT, ARNA, KURA, AKRO, STOK, TCDA, DTIL, INSP, NBIX, GOSS, ORTX, NKTR, GLPG, EIGR,
• Sold Out: RARX,

For the details of Cormorant Asset Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/cormorant+asset+management%2C+llc/current-portfolio/portfolio

1. SPDR S&P 500 (SPY) - 1,000,000 shares, 12.82% of the total portfolio.
2. Turning Point Therapeutics Inc (TPTX) - 3,056,797 shares, 6.79% of the total portfolio. Shares reduced by 10.01%
3. Principia Biopharma Inc (PRNB) - 2,100,000 shares, 6.20% of the total portfolio. Shares added by 5.48%
4. BridgeBio Pharma Inc (BBIO) - 2,950,000 shares, 4.25% of the total portfolio. Shares added by 17.40%
5. ChemoCentryx Inc (CCXI) - 2,025,000 shares, 4.05% of the total portfolio. Shares reduced by 30.17%

Cormorant Asset Management, LLC initiated holding in Acceleron Pharma Inc. The purchase prices were between $50.95 and $95.31, with an estimated average price of $77.26. The stock is now traded at around $99.37. The impact to a portfolio due to this purchase was 3.69%. The holding were 825,000 shares as of .

Cormorant Asset Management, LLC initiated holding in Agenus Inc. The purchase prices were between $1.92 and $4.39, with an estimated average price of $3.23. The stock is now traded at around $3.73. The impact to a portfolio due to this purchase was 1.48%. The holding were 12,174,486 shares as of .

Cormorant Asset Management, LLC initiated holding in Cabaletta Bio Inc. The purchase prices were between $6 and $18.67, with an estimated average price of $13.79. The stock is now traded at around $7.31. The impact to a portfolio due to this purchase was 0.76%. The holding were 2,105,846 shares as of .

Cormorant Asset Management, LLC initiated holding in Homology Medicines Inc. The purchase prices were between $12.5 and $22.04, with an estimated average price of $17.1. The stock is now traded at around $15.78. The impact to a portfolio due to this purchase was 0.46%. The holding were 600,000 shares as of .

Cormorant Asset Management, LLC initiated holding in Insmed Inc. The purchase prices were between $13.63 and $33.98, with an estimated average price of $23.78. The stock is now traded at around $28.42. The impact to a portfolio due to this purchase was 0.29%. The holding were 362,273 shares as of .

Cormorant Asset Management, LLC initiated holding in Arcturus Therapeutics Holdings Inc. The purchase prices were between $9.31 and $18.26, with an estimated average price of $12.77. The stock is now traded at around $40.06. The impact to a portfolio due to this purchase was 0.18%. The holding were 262,037 shares as of .

Cormorant Asset Management, LLC added to a holding in Eidos Therapeutics Inc by 121.91%. The purchase prices were between $38.03 and $58.69, with an estimated average price of $51.13. The stock is now traded at around $49.46. The impact to a portfolio due to this purchase was 1.47%. The holding were 1,100,000 shares as of .

Cormorant Asset Management, LLC added to a holding in Omeros Corp by 65.49%. The purchase prices were between $9.03 and $19.72, with an estimated average price of $13.32. The stock is now traded at around $15.04. The impact to a portfolio due to this purchase was 0.66%. The holding were 2,523,700 shares as of .

Cormorant Asset Management, LLC added to a holding in AnaptysBio Inc by 203.53%. The purchase prices were between $12.82 and $18.69, with an estimated average price of $15.2. The stock is now traded at around $19.25. The impact to a portfolio due to this purchase was 0.52%. The holding were 1,107,900 shares as of .

Cormorant Asset Management, LLC added to a holding in Blueprint Medicines Corp by 30.43%. The purchase prices were between $48.11 and $82.22, with an estimated average price of $64.89. The stock is now traded at around $76.32. The impact to a portfolio due to this purchase was 0.31%. The holding were 450,000 shares as of .

Cormorant Asset Management, LLC added to a holding in Myovant Sciences Ltd by 30.00%. The purchase prices were between $6.55 and $15.52, with an estimated average price of $11.33. The stock is now traded at around $16.70. The impact to a portfolio due to this purchase was 0.23%. The holding were 2,600,000 shares as of .

Cormorant Asset Management, LLC added to a holding in Sorrento Therapeutics Inc by 25.00%. The purchase prices were between $1.57 and $4.76, with an estimated average price of $2.91. The stock is now traded at around $4.80. The impact to a portfolio due to this purchase was 0.09%. The holding were 5,000,000 shares as of .

Cormorant Asset Management, LLC sold out a holding in Ra Pharmaceuticals Inc. The sale prices were between $40.51 and $48.01, with an estimated average price of $46.53.

Cormorant Asset Management, LLC reduced to a holding in Reata Pharmaceuticals Inc by 40.32%. The sale prices were between $124.16 and $247.74, with an estimated average price of $194.02. The stock is now traded at around $160.45. The impact to a portfolio due to this sale was -2.78%. Cormorant Asset Management, LLC still held 487,206 shares as of .

Cormorant Asset Management, LLC reduced to a holding in Mirati Therapeutics Inc by 33.72%. The sale prices were between $69.78 and $128.86, with an estimated average price of $90.44. The stock is now traded at around $108.86. The impact to a portfolio due to this sale was -2.3%. Cormorant Asset Management, LLC still held 850,000 shares as of .

Cormorant Asset Management, LLC reduced to a holding in ChemoCentryx Inc by 30.17%. The sale prices were between $32.73 and $50.78, with an estimated average price of $42.52. The stock is now traded at around $60.28. The impact to a portfolio due to this sale was -1.43%. Cormorant Asset Management, LLC still held 2,025,000 shares as of .

Cormorant Asset Management, LLC reduced to a holding in CRISPR Therapeutics AG by 36.96%. The sale prices were between $33.68 and $62.53, with an estimated average price of $51.94. The stock is now traded at around $67.34. The impact to a portfolio due to this sale was -0.93%. Cormorant Asset Management, LLC still held 630,400 shares as of .